The contraindications of Sunitinib involve specific populations, dietary restrictions, and medication conditions, and must be strictly followed to reduce treatment risks. The following provides a detailed explanation from three aspects: taboo groups, food interactions, and special restrictions.

1. Taboo population

(1) Pregnant women: May cause fetal malformation, confirm pregnancy status before medication, and take contraceptive measures during treatment and 4 weeks after discontinuation of medication.

(2) Severe liver dysfunction: Child Pugh Class C patients are contraindicated, and mild to moderate damage requires reduced monitoring.

(3) History of QT interval prolongation: Patients with uncorrected hypokalemia/magnesemia are contraindicated and require regular electrocardiogram monitoring.

2. Forbidden foods

(1) Grapefruit/grapefruit juice: inhibits CYP3A4 metabolic enzymes, may increase blood drug concentration, leading to toxicity risk.

(2) High fat diet: It is recommended to take on an empty stomach or after a low-fat meal. Fat intake>50g can reduce bioavailability by 30%.

3. Restrictive conditions

(1) Before and after surgery: Medication should be discontinued 2 weeks before major surgery and resumed after wound healing.

(2) Combination therapy: Strong CYP3A4 inhibitors (such as clarithromycin) need to be reduced by 50%, while inducers (such as rifampicin) need to be increased.

(3) Cardiovascular disease: Use with caution in patients with recent myocardial infarction or heart failure, and monitor left ventricular ejection fraction.